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Objective: Hypertension causes 7.5 million deaths annually worldwide. Antihypertensive drugs cause side effects, potentially leading to non-
adherence, hence uncontrolled hypertension and increased risk of cardiovascular morbidity and mortality. Therefore, there has been increasing 
interest in alternative pharmacological treatments for hypertension, one of which is black cumin, or Nigella sativa, a traditional medicine that has 
been empirically used. This evidence-based case report aims to evaluate the current evidence for the effectiveness of Nigella sativa in reducing 
blood pressure in a mildly hypertensive patient.  
Methods: A literature search was performed on MEDLINE, TRIP Database, Clinical Key, ScienceDirect, and DynaMed, using the keywords “nigella 
sativa”, “hypertension”, and “blood pressure” with all their synonyms and related terms. The included studies were two systematic reviews and two 
clinical trials, which were then critically appraised.  
Results: Out of the four studies, three were considered valid. In terms of importance, Sahebkar et al. showed a reduction of the weighted mean 
difference (WMD) by Nigella sativa: −3.26 mmHg, 95% CI: −5.10, −1.42, I2 = 59% for systolic blood pressure and WMD: −2.80 mmHg, 95% CI: −4.28, 
−1.32, I2
Conclusion: The current evidence for the effect of Nigella sativa in lowering blood pressure is limited. However, one study gives strong evidence for 
significant antihypertensive effects of Nigella sativa. In mild hypertension, Nigella sativa could be one of the therapeutic options. 
 = 60% for diastolic blood pressure. Badar et al. concluded that Nigella sativa significantly reduced systolic and diastolic blood pressure 
compared with the control group. Two studies were considered applicable to our patient in question.  
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INTRODUCTION 
Hypertension, or high blood pressure, is a condition in which elevated 
pressure persists within the blood vessels. The pressure in the blood 
vessels is created by blood flow that forces against the inner walls of 
the vessels. The latest data from the World Health Organization shows 
that hypertension is estimated to cause 7.5 million deaths annually or 
about 12.8% of all deaths worldwide. It also causes 57 million 
disability adjusted life years (DALYs) or about 3.7% of total DALYs [1]. 
The prevalence of this non-communicable disease is rising in 
developing countries, and in Indonesia, which is the fourth most 
populous country in the world. The burdens of diabetes, heart disease, 
stroke, and hypertension have increased in the past 20 y. According to 
Indonesian Basic Health Research (or Riset Kesehatan Dasar), the 
prevalence of hypertension in Indonesia was 25.8% in 2013. 
According to Sample Registration System Indonesia, hypertension 
with complications accounted for about 5.3% of all deaths in Indonesia 
in 2014, making it the fifth highest cause of death [2, 3]. Moreover, the 
burden of hypertension also comes from the low rate of diagnosis and 
treatment. Only 1/3 of patients with hypertension have been 
diagnosed, while only 0.7% of those diagnosed with hypertension are 
taking antihypertensive medications [3]. 
Currently, the available treatments for hypertension include various 
classes of antihypertensive drugs, such as angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers, calcium channel 
blockers, and thiazide-type diuretics [4]. In a prospective cohort study 
in the United States, side effects of antihypertensive drugs occurred in 
85% of the patients, resulting in non-adherence of 34.5% of patients to 
the treatments.[5] Such non-adherence is believed to be the main 
cause of uncontrolled hypertension, which then increases the risk of 
heart failure, stroke, and mortality [6, 7] The adverse effects of these 
drugs along with the relatively high costs, have contributed to the 
rising interest in herbal treatment for hypertension [8].  
Nigella sativa, also known as black cumin, black seed, habitus sauda, or 
jintan hitam in Indonesia, is a traditional medicine that has been used 
in various medical conditions since hundreds of years ago [9]. 
Preclinical and clinical studies have suggested N. sativa as antioxidants 
and diuretic agents, and its effects in reducing sympathetic activities, 
lowering lipids, increasing nitric oxide production to prevent arterial 
rigidity, reducing appetite and many others, all of which contribute to 
its potential use as an antihypertensive agent [10-12]. However, 
despite its empirical use through generations, the scientific evidence 
on the antihypertensive effects of N. sativa is somehow limited and 
often inconsistent. Therefore, this evidence-based case report aims to 
critically analyze and weigh the available evidence for the effects of N. 
sativa on alleviating hypertension. 
Clinical question 
A 45-year-old man participated in a blood pressure screening 
program. His blood pressure reading was 130/90 mmHg. He and his 
immediate family had no history of cardiovascular diseases. The 
patient was interested to know if he could use N. sativa supplements 
to control his blood pressure. 
MATERIALS AND METHODS  
A search of literatures was performed on September 15th to 16th, 
2018 on MEDLINE, TRIP Database, Clinical Key, ScienceDirect, and 
DynaMed. The keywords used were “nigella sativa”, “hypertension” 
and “blood pressure” with all their synonyms and related terms. 
Table 1 below shows the terminology used in each database during 
the search. 
The eligible articles were clinical trials, systematic reviews and 
meta-analyses with blood pressure (systolic and diastolic) as one of 
the outcomes of the study, limited to studies in human and 
published in English in the last 5 y. All guidelines and review articles 
were excluded. The search strategy is illustrated in fig. 1. After 
screening the literatures and reading the full texts, therapy articles 
or systematic reviews were critically appraised with consensus of all 
authors based on the guideline established by the Center of 
Evidence-Based Medicine, University of Oxford. 
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Table 1: Search terms used in the five databases 
Database Terminology Hits Selected 
MEDLINE (((hypertension) OR blood pressure) AND nigella sativa) AND ((Review[ptyp] OR Meta-Analysis[ptyp] OR 





(hypertension)(nigella sativa)(blood pressure) 13 0 
ClinicalKey ((Nigella sativa) OR 'blood pressure') AND 'nigella sativa' 21 0 
ScienceDirect TITLE-ABSTR-KEY(“hypertension” OR “blood pressure”) AND TITLE-ABSTR-KEY (nigella sativa) 6 0 
DYNAMED ((Nigella sativa) OR 'blood pressure') AND 'nigella sativa' 3 1 
 
 
Fig. 1: Flowchart of the search strategy 
 
RESULTS 
Following the literature search, four articles were found to be 
eligible for this evidence-based case report [13–16] the design and 
summary of the articles can be found in table 2.  
These two articles are prospective cohort studies with a level of 
evidence of 2b. The study by Badar A, et al. [13] has a larger sample 
size and longer duration compared with the study by Rizka A, et al. 
[14]. The former is a single-blind non-randomized clinical trial, 
whereas the latter is a double-blind randomized controlled trial. The 
remaining two articles chosen are systematic reviews, the critical 
appraisal of which is explained in table 4. The review by Sahebkar A, 
et al. [15] includes a meta-analysis, while the review by Mohtashami 
A, et al. does not [16]. 
 
Table 2: Summary of the selected articles 
  Badar, et al. (2017) Rizka, et al. (2017) Sahebkar, et al. (2016) Mohtashami, et al. (2016) 










Systematic review of clinical trials 
 
Subjects/Materials Patients with 
type 2 diabetes 
and hypertension 
57 patients in 
each group, 




38 patients in 
each group, 
total of 76 
Hypertensive and normotensive 
patients; pooled total of 860 
patients 11 RCTs from PubMed, 
Medline, Cochrane Collaboration 
Library, SCOPUS, Web of Science, 
and Google Scholar 
Patients with diabetes, patients with 
metabolic syndrome, patients with 
hyperlipidemia, patients with hypertension, 
and healthy subjects; pooled total of 1531 
PubMed, Google Scholar, Thomas Reuters 
Web of Science, and Cochrane 
Intervention N. sativa 
seeds: 500-mg  
oral capsules, 2 
g/day for 12 mo 
N. sativa seeds: 
300-mg oral 
capsules, 2 times 
a day for 28 d 
N. sativa oil (n=3) 
N. sativa 
powder (n=8) 
N. sativa extract N. sativa oil 
N. sativa powder Dose of 200 mg to 5 g. 
Duration of 2 w to 6 mo 
Control Placebo (activated 
Charcoal capsules) 
Placebo Placebo (n=10) 
Standard treatment (n=1) 
Not clear 
Results Significant 
decrease in SBP, 
DBP, and MAP 
Clinically 
Significant 
decrease in SBP 
but not DBP 
Short-term 
treatment with N. sativa 
significantly reduced SBP 
and DBP 
N. sativa at different doses and for different 
durations can change various clinical and 
biochemical parameters, but less 
pronounced effect on blood pressure 
RCTs, randomized controlled trials; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure, Out of the four articles 
chosen, two articles are original articles, the critical appraisal of which is shown in table 3.  
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Table 3: Critical appraisal of the two clinical trials 
  Badar A, et al. (2017) Rizka A, et al. (2017) 
Level of evidence 2b 2b 
Sample size 114 76 
Length of treatment 12 mo 28 d 
Validity Randomization − + 
Group similarity + ? 
Equal treatment + + 
Loss to follow-up (%) 15.8 N/A 
Drop-out (%) N/A 9.2 
Blinding Single Double 
Importance Changes in blood pressure 
(endpoint compared with baseline) 
Systolic BP:  
9.66 mmHg 
Diastolic BP:  
3.51 mmHg  
Systolic BP:  
14.6 mmHg 
Diastolic BP:  
3.9 mmHg 
P values (treatment vs placebo) Systolic BP: 0.053 
Diastolic BP: 0.024 
Systolic BP: 0.36 
Diastolic BP: 0.35 
Applicability Patient similarity + + 
Feasibility of treatment + + 
Benefits outweigh harm + + 
+shown clearly in the article; − not being done;? not stated clearly; levels of evidence based on Oxford Centre for Evidence-Based Medicine; BP: 
blood pressure 
 
Table 4: Critical appraisal of the two systematic reviews 
 Validity Sahebkar, et al. (2016) Mohtashami, et al. (2016) 
Did the systematic review address a 
relevant question? 
Yes Yes 
Were the criteria used to select 
articles for inclusion appropriate? 
Yes Yes 
Is it likely that important, relevant 
studies were missed? 
No No 
Was the validity of the selected 
studies appraised? 
Yes No 
Were the included studies 
sufficiently valid for the type of 
question asked? 
Yes No 
Were the results of the selected 
studies similar to each other? 
Yes No 
Importance   
What are the overall results of the 
meta-analysis? 
Treatment with N. sativa has a significant effect on lowering 
systolic blood pressure (WMD: −3.26 mmHg, 95% CI: −5.10, 
−1.42, I2 = 59%) and diastolic blood pressure (WMD: −2.80 
mmHg, 95% CI: −4.28, −1.32, I2
Four out of nine studies have shown that N. 
sativa can reduce blood pressure. The 
effect however was not significant in the 
other five trials   = 60%) 
How precise were the results? Precise, with 95% CI for reduced blood pressure after 
treatment with N. sativa 
No statistical data were given in the review 
Applicability   
Can the results be applied to our 
patient? 
Yes No 
Were all the clinically important 
outcomes considered? 
Yes No 
Do the benefits outweigh the harm? Yes Benefits cannot be concluded 
 
Owing to the design of the single-blind, non-randomized clinical trial 
by Badar, et al. [13], its validity is weaker compared with the double-
blind, randomized controlled trial by Rizka, et al. [14] Nevertheless, 
the validity of the study by Rizka, et al. [14] is also limited by the 
unknown significance in group similarity and the short duration of 
treatment. In both clinical trials, those lost to follow-up or dropping 
out were below 20%, and thus had little effect on their validity. The 
changes in systolic and diastolic blood pressures at the end of the 
trial compared with the baseline were taken into account to 
determine the clinical importance. Only the change in systolic blood 
pressure of more than 10 mmHg in the study by Rizka et al. [14] was 
of clinical importance. Meanwhile, the P values of differences in the 
systolic and diastolic blood pressures between the treatment group 
and the placebo group were considered to determine its statistical 
significance. Only the P value for the difference in diastolic blood 
pressure in the study by Badar et al. [13] was less than 0.05, and 
thus statistically significant. Overall, both studies were weak in 
validity as only one out of four parameters was met in each study. 
Both clinical trials were considered to be applicable though because 
of their apparent feasibility of treatment and the benefits over the 
reported harms. Moreover, the study by Badar, et al. [13] was 
considered stronger with a higher patient similarity and a narrower 
range of age and blood pressures. In the study by Rizka, et al. [14], 
the patients were elderly with a mean systolic blood pressure of 160 
mmHg, which was higher than that in the study by Badar, et al. 
The meta-analysis by Sahebkar, et al. [15] was valid, relevant, 
important, and applicable to our question and showed a level of 
evidence of 1a. Sahebkar, et al. [15] included all valid studies (RCTs, 
published before 30 August 2015) to determine the effect of N. 
sativa on lowering blood pressure. The study analyzed differences in 
blood pressure reduction using I2 index and X2 statistics, measuring 
inter-study heterogeneity. Each study included in the meta-analysis 
was assessed for publication bias using Egger’s test and no bias was 
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found. Importance was met with −3.26 mmHg, 95% CI: −5.10, −1.42, 
I2 = 59% for SBP and weighted mean difference: −2.80 mmHg, 95% 
CI: −4.28, −1.32, I2
DISCUSSION 
 = 60% for DBP. Meanwhile, we concluded that the 
systematic review by Mohtashami, et al. [16] was not valid or 
applicable to our question. The study was not focused on blood 
pressure but rather on blood parameters and anthropometric 
indices. Mohtashami, et al. [16] was unable to make a conclusion on 
the effects of N. sativa on reducing blood pressure because of the 
different characteristics across the selected studies. 
Considering the validity components, the clinical study by Badar, et 
al. [13] may not suffice. Although there was group similarity in this 
study, the groups were not assigned randomly. Together with the 
single-blind design, this poses a notable risk of bias in the study 
thereby reducing its validity. Meanwhile, the study by Rizka, et al. 
[14] claimed to have comparable baseline characteristics in the two 
groups, there were no statistical data presented to indicate 
statistical significance. While this may decrease the validity of the 
study to a certain extent, it could still be more valid with its double-
blind design than the study by Badar, et al. [13] 
In terms of importance, both clinical trials seemed weak as only one 
out of four parameters favored the treatment using N. sativa. 
Notably however, in both studies, changes in blood pressure and the 
P values of difference between the treatment group and placebo 
were the only values available for appraisal of importance. The 
relative risk and the number needed to treat could not be obtained 
without any data on the event rates. Both studies only presented the 
mean values of systolic and diastolic blood pressure in the treatment 
and placebo groups, without specifying the number of events of 
hypertension in each group. This means that the ratio of benefit and 
harm in the treatment using Nigella sativa cannot be quantified. 
These inevitably result in a suboptimal appraisal of the importance 
of these clinical trials. As for their applicability, both studies 
presented adequate evidence in favor of using N. sativa in patients 
with hypertension, mainly because of the feasibility and safety. N. 
sativa is easily found in Indonesia and has been empirically used in 
Indonesia as dietary supplements [17]. The reported adverse events 
in both studies were minimal, hence strengthening their 
applicability. The study by Rizka, et al. [14] is, however, less 
applicable to our question because their patients were elderly with a 
mean SBP of 160 mmHg. Our patient is a middle-aged man with mild 
hypertension of SBP of 130 mmHg. The difference in blood 
pressures may be clinically significant and may affect the translation 
of the results to our patient. 
The review by Sahebkar, et al. [15] was shown to be valid because of 
its focus on the question asked, appropriate inclusion criteria, 
similar results between studies, and good coverage of the included 
studies. Eleven studies were included, ranging from treatment 
duration of 4–12 w with both hypertensive and normotensive 
patients. No publication bias was identified in all 11 studies. Random 
effect models were used when comparing with a control group, 
concluding that the group receiving N. sativa had a mean decrease of 
3.26 and 2.80 mmHg in systolic and diastolic blood pressures, 
respectively. The effect was also found to be important in lowering 
blood pressure in human, but the reduction of 3.26/2.80 mmHg was 
not clinically significant in controlling hypertension. Besides, the 
study was conducted in a heterogeneous population with patient 
differences in demographics and baseline clinical characteristics. It 
was also limited by the short duration of the included studies, which 
only ranged from 4 to 12 w, and hence was not indicative for the 
effect of long-term use of N. sativa. 
In contrast, the systematic review made by Mohtashami, et al. [16] 
demonstrated low validity. This judgment was based on the lack of 
information about how the authors concluded the effects of each 
included trial. Moreover, no statistical data were provided by 
Mohtashami, et al. [16] making results in the study less important. 
Among the four studies considered, we concluded that the meta-
analysis by Sahebkar, et al. [15] was the strongest evidence available 
for our research question owing to its relatively high validity, 
importance, and applicability. 
Unfortunately, the mechanism of how N. sativa reduces blood 
pressure is not well defined. Several factors can be assumed to play 
a role in this mechanism based on the components of N. sativa. 
Thymoquinone acts on serotoninergic and muscarinic receptors, 
thymol acts on calcium ion channels, and other components induce 
diuretic effects through mediating signaling pathways [18-20]. 
Thymoquinone, flavonoids, and polyphenols also have antioxidant 
activity that dilates blood vessels by nitric oxide production [21-23]. 
Furthermore, N. sativa also lowers blood pressure via the diuretic 
effect; the effect of a dose of 5 mg/kg of N. sativa was comparable 
with that of furosemide, a frequently used diuretic. This diuretic 
effect helps to decrease blood pressure through reduction of 
electrolytes and water content, thus reducing cardiac output [24]. 
However, these results were obtained in a strict, laboratory-
controlled environment; hence, their proposed mechanisms must be 
interpreted with caution. The exact mechanism of action of N. sativa 
is therefore still indefinite. 
The limitation of this study is that in the appraisal of the importance 
of the clinical trials, the relative risk and the number needed to treat 
could not be assessed owing to the lack of data of the event rates in 
the two clinical trials. The data were unpublished and we have yet to 
be in correspondence with the authors of these studies for the 
relevant data. In general, we have also found that the use of N. sativa 
in alleviating high blood pressure is relatively unexplored, resulting 
in the limited number of studies available. We hope that this study 
will prompt more clinical trials on the use of N. sativa in treating 
hypertension, which will help to determine its effects on blood 
pressure and its safety during long-term use. 
As for the patient in our case, the recommended management based on 
the 2017 ACC/AHA guidelines is nonpharmacologic therapy and re-
evaluation in 3–6 mo after starting therapy [4]. Nonpharmacologic 
therapy may include a combination of changes in diet and physical 
activity. As for the use of N. sativa supplements to control hypertension, 
we have to explain to the patient that the current evidence is still limited, 
despite a favorable tendency towards the antihypertensive effects. The 
patient can also be educated on the importance of a balanced diet, 
physical activity, and routine health check-up. 
CONCLUSION 
In conclusion, the current evidence for the use of N. sativa in 
lowering blood pressure is still limited, with the strongest evidence 
for its significant antihypertensive effect from a meta-analysis of 
RCTs. Other clinical trials also suggested clinically significant 
decreases in systolic blood pressure. Considering its benefits of 
alleviating hypertension and its relatively few reported side effects, 
further research is encouraged to achieve a better understanding of 
the use of N. sativa as antihypertensive treatment and to provide 
high-quality evidence to support healthcare policies and clinical 
decisions. This should benefit millions of people affected by 
hypertension and cardiovascular diseases worldwide. 
ACKNOWLEDGMENT 
We thank all the staff of the Department of Medical Pharmacy in the 
Faculty of Medicine of Universitas Indonesia for the opportunity to 
prepare this report. This article was presented at The 3rd 
International Conference and Exhibition on Indonesian Medical 
Education and Research Institute (ICE on IMERI 2018), Faculty of 
Medicine, Universitas Indonesia, Jakarta, Indonesia. We thank the 3rd
AUTHORS CONTRIBUTIONS 
 
ICE on IMERI Committee who had supported the peer review and 
manuscript preparation before submitting to the journal. 
All the author have contributed equally 
CONFLICTS OF INTERESTS 
There is no conflict of interest in the preparation and publication of 
this study. 
REFERENCES 
1. World Health Organization. WHO Raised blood pressure. 
Who.int; 2018. Available from: http://www.who.int/gho/ 
Lokeswara et al. 




accessed on 02 Oct 2018] 
2. Badan Penelitian dan Pengembangan Kesehatan. Riset 
Kesehatan Dasar 2013. Jakarta: Kementrian Kesehatan 
Republik Indonesia; 2013. 
3. Kementrian Kesehatan Republik Indonesia. Sebagian Besar 
Penderita Hipertensi tidak Menyadarinya. Depkes.go.id; 2017. 
Available from: http://www.depkes.go.id/article/view/ 
17051800002/sebagian-besar-penderita-hipertensi-tidak-
menyadarinya.html. [Last accessed on 02 Oct 2018] 
4. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, 
Himmelfarb CD, et al. 
2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NM
A/PCNA Guideline for the prevention, detection, evaluation, 
and management of high blood pressure in adults: a report of 
the American College of Cardiology/American Heart 
Association Task Force on clinical practice guidelines. J Am Coll 
Cardiol 2018;71:e127. 
5. Tedla YG, Bautista LE. Drug side effect symptoms and 
adherence to antihypertensive medication. Am J Hypertens 
2016;29:772–9. 
6. Morgado M, Rolo S, Macedo AF, Pereira L, Castelo-Branco M. 
Predictors of uncontrolled hypertension and antihypertensive 
medication nonadherence. J Cardiovasc Dis Res 2010;1:196–202. 
7. Gu Q, Burt VL, Paulose Ram R, Yoon S, Gillum RF. High blood 
pressure and cardiovascular disease mortality risk among U. S. 
adults: the third National Health and Nutrition Examination Survey 
mortality follow-up study. Ann Epidemiol 2008;18:302–9. 
8. Disi SS, Anwar MA, Eid AH. Anti-hypertensive herbs and their 
mechanisms of action: part I. Front Pharmacol 2015;6:323. 
9. Salem ML. Immunomodulatory and therapeutic properties of the 
Nigella sativa L. seed. Int J Immunopharmacol 2005;5:1749–70. 
10. Ubru U, Burak U, Yusuf S, Reyhan B, Arif K, Faruk TH. 
Cardioprotective effects of Nigella sativa oil on cyclosporine a-
induced cardiotoxicity in rats. Basic Clin Pharmacol Toxicol 
2008;103:574–80. 
11. Mathur ML, Gaur J, Sharma R, Haldiya KR. Antidiabetic 
properties of a spice plant Nigella sativa. J Endocrinol Metab 
2011;1:1–8. 
12. Nader MA, El-Agami DS, Suddek GM. Protective effects of 
propolis and thymoquinone on development of atherosclerosis 
in cholesterol-fed rabbits. Arch Pharm Res 2010;337:637–43. 
13. Badar A, Kaatabi H, Bamosa A, Al-Elq A, Abou-Hozaifa B, Lebda 
F, et al. Effect of Nigella sativa supplementation over a one-year 
period on lipid levels, blood pressure and heart rate in type-2 
diabetic patients receiving oral hypoglycemic agents: 
nonrandomized clinical trial. Ann Saudi Med 2017;37:56–63.  
14. Rizka A, Setiati S, Lydia A, Dewiasty E. Effect of Nigella sativa 
seed extract for hypertension in elderly: a double-blind, 
randomized controlled trial. Acta Med Indones 2017;49:7.  
15. Sahebkar A, Soranna D, Liu X, Thomopoulos C, Simental Mendia 
LE, Derosa G, et al. A systematic review and meta-analysis of 
randomized controlled trials investigating the effects of 
supplementation with Nigella sativa (black seed) on blood 
pressure. J Hypertens 2016;34:2127–35.  
16. Mohtashami A, Entezari M. Effects of nigella sativa 
supplementation on blood parameters and anthropometric 
indices in adults: a systematic review on clinical trials. J Res 
Med Sci 2016;21:3.  
17. Herlina, Aziz SA, Kurniawati A, Faridah DN. Changes of 
thymoquinone, thymol, and malondialdehyde content of black 
cumin (Nigella sativa L.) in response to Indonesia tropical 
altitude variation. HAYATI J Biosci 2017;24:156–61.  
18. Teres S, Barcelo Coblijn G, Benet M, Alvarez R, Bressani R, 
Halver JE, et al. Oleic acid content is responsible for the 
reduction in blood pressure induced by olive oil. Proc Natl Acad 
Sci 2008;105:13811–6.  
19. Tahir KE, Ashour MM, Al-Harbi MM. The cardiovascular actions 
of the volatile oil of the black seed (Nigella sativa) in rats: 
elucidation of the mechanism of action. Gen Pharmacol 
1993;24:1123–31. 
20. Tahir KE, Ageel AM. Effect of volatile oil of Nigella sativa on the 
arterial blood pressure and heart rate of the guinea pig. Saudi 
Med J 1994;2:163–8. 
21. Peixoto Neves D, Silva Alves KS, Gomes MD, Lima FC, Lahlou S, 
Magalhaes PJ, et al. Vasorelaxant effects of the monoterpenic 
phenolisomers, carvacrol and thymol, on rat isolated aorta. 
Fundam Clin Pharmacol 2010;24:341–50. 
22. Andriambeloson E, Magnier C, Haan Archipoff G, Lobstein A, 
Anton R, Beretz A, et al. Natural dietary polyphenolic 
compounds cause endothelium-dependent vasorelaxation in 
rat thoracic aorta. J Nutr 1998;128:2324–33. 
23. Zaoui A, Cherrah Y, Lacaille Dubois MA, Settaf A, Amarouch H, 
Hassar M. Diuretic and hypotensive effects of Nigella sativa in 
the spontaneously hypertensive rat. Therapie 2000;55:379–82. 
 
